TRITON Study to Target Biomarkers for Patients With Select NSCLC Mutations

1 year ago 44

The TRITON study is evaluating tremelimumab/durvalumab/chemotherapy vs pembrolizumab/chemotherapy in non–small lung cancer (NSCLC) with STK11 and/or KEAP1 and/or KRAS mutations.

1. Homepage
2. Lung Cancer
3. TRITON Study to Target Biomarkers for Patients With Select NSCLC Mutations